MedPath

Stay-On oral liquid for prospective sexual functio

Not Applicable
Conditions
Health Condition 1: null- In sexually active men suffering from Erectile Dysfunction, Premature Ejaculation or Low Libido.
Registration Number
CTRI/2017/03/008158
Lead Sponsor
SHREE MARUTI HERBA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
26
Inclusion Criteria

1.Male married patients aging 21 â?? 55 years

2.The patients who have erectile insufficiency, premature ejaculation or lower sex drive for at least 3 month.

3.Subjects with controlled diabetes mellitus and/or hypertension on monotherapy or low dose combination therapy (accepted co-medication in obese and overweight subjects, for example, antidiabetic drug metformin and hypertension, for example, antihypertensive drug amlodipine, atenolol, perindopril).

4.The subjects should be sexually active and in a monogamous relationship with their heterosexual partner. Men must be sexually active: A man is considered sexually active if he has been engaged in sexual activity with a partner during the past 4 weeks (at least once) and plans to be active until end of study (unless due to travel or other practical reasons).

5.Erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire <= 18.

6.Fluent and literate in local language with the ability to read, comprehend and record information on the IIEF-15 questionnaire.

7.Able to swallow and retain oral medication.

8.Cooperative and understanding skills.

9.Patient willing to provide written informed consent.

10.Patient willing to give specimen of semen

11.Patients ready to abstain from using any drug other than Investigational Product for the treatment of the studied condition, except in emergencies, in which case the responsible party must be immediately notified.

Exclusion Criteria

1.History or evidence of prostate cancer

2.Current or prior use of any drugs with anti-androgenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents) within the 6 months prior to visit 1 (screening).

3.Current or 1 month prior use of PDE-5 inhibitors for Erectile Dysfunction, Anabolic steroids, Use of phyto-therapy for sexual dysfunction within 2 weeks prior to screening visit.

4.Any recent major surgical procedures.

5.Spinal cord injury

6.Radical prostatectomy

7.Radical pelvic surgery

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in (EF) â??Erectile functionâ?? domain score of the IIEF-15 questionnaire at end of study.Timepoint: at end of study.
Secondary Outcome Measures
NameTimeMethod
Proportion of patients experienced an adverse eventsTimepoint: at end of study.
© Copyright 2025. All Rights Reserved by MedPath